OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi in Lung Cancer

OSE Immunotherapeutics Receives €8.4 M in Public Funding
to Support the Registration Phase 3 Clinical Trial
of Cancer Vaccine Tedopi in Lung Cancer

Nantes, France – April 10, 2024 – 6:00 pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the Company has received €8.4 million in non-dilutive funding under the “i-Démo” call for projects as part of the plan “France 2030” operated by Bpifrance on behalf of the State. This plan aims at developing industrial companies in growth markets that create value and competitiveness for the French economy and also contribute to energy, ecological and digital transitions. This financial support applies from the feasibility study to marketing.

This public funding will support the registration Phase 3 clinical trial of neoepitope-based cancer vaccine Tedopi, in second line treatment in HLA-A2 positive non-small cell lung patients with secondary (acquired) resistance to anti-PD-(L)1 immunotherapy. This new national support adds up to the €1.5 million funding from Bpifrance * announced in June 2023 to support the development of a companion diagnostic test (HLA-A2) associated with Tedopi’s registration in the same indication.

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: « We thank the State and Bpifrance for renewing their confidence and supporting us with this funding. It will enable the Company to accelerate the last step of clinical development of our cancer vaccine Tedopi. This innovation will meet the important medical need of non-small cell lung cancer patients who are failing after immunotherapy, and who do not have today any approved therapeutic options. Following FDA approval on the trial protocol in early 2024, we will be able to start this confirmatory Phase 3 in the United States in the coming weeks and then, once we receive approval from the EMA, in Europe and in France where many clinical sites will be set up. We thank particularly the international groups of clinical investigators and lung cancer experts who, from the beginning, support us and are committed to advance the clinical development of Tedopi towards a potential new standard treatment in second line of metastatic or advanced lung cancer”.